Biotech Companies Are Increasingly Worried About Trump's Visa Crackdown

| February 24, 2017

article image
From tiny startups to global giants, the companies that sustain the $324 billion U.S. biotech industry are increasingly alarmed as President Donald Trump considers following his controversial travel ban with restrictions on skilled foreign immigrants. Bloomberg's Doni Bloomfield reports from the nation's biotech hub in Cambridge, Massachusetts.

Spotlight

Vigilance Biotechnology LLC

Vigilance Biotechnology™ provides medicinal healthcare consultant services and biotechnology business services. The three major service products of Vigilance Biotechnology are: Personal Medicinal Consultant Services The Personal Medicinal Consultant Service provides clients with healthcare information that can help them achieve better health. Vigilance develops custom safety evaluation reports for clients using multiple prescription drugs, over-the-counter (OTC) products, herbal, and dietary supplements. Vigilance suggests dietary supplements as alternatives to prescription medicines that can be used to help achieve better health and athletic performance. Biotechnology Business Plan Services Vigilance Biotechnology provides four unique business plan services to its clients. Vigilance quickly evaluate and strengthen pre-existing biotechnology business plans. We work directly with clients to develop outstanding new biotechnology business plans.

OTHER ARTICLES

Ruminating on Bioprocessing 4.0

Article | February 18, 2020

The Bioprocessing 4.0 concept seeks to apply automation and technology to the digital transformation of biologics manufacturing. As the paradigm moves forward, it faces barriers to its adoption, according to Eric Langer, president of BioPlan Associates. “Perhaps the greatest challenges involve unsecured links and adapting the applications to areas where automation is critically needed today,” says Langer. “Unresolved security issues could seriously affect a company’s data in a regulated environment, so they will need to have iron-clad anti-hacking protection in place. Unfortunately, cyber security is not yet a top focus for the industry.”

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 24, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Biotech: Finding The DNA For Success

Article | April 3, 2020

The integration of artificial intelligence within life sciences is making drug discovery and development more innovative, less labor intensive and more cost-effective, says Deloitte’s annual global outlook. According to Deloitte’s 2020 Global Life Sciences Outlook, the biotech sector is at an inflection point. To prepare for the future and remain relevant in the ever-evolving business landscape, biopharma and medtech organizations will be looking for new ways to create value and new metrics to make sense of today’s wealth of data, the report overview says. As data-driven technologies provide biopharma and medtech organizations with treasure troves of information, and automation takes over some mundane tasks, new talent models are emerging based on purpose and meaning. The integration of artificial intelligence (AI) and machine learning approaches within life sciences is making drug discovery and development more innovative, time-effective and cost-effective, the Deloitte report states.

Read More

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | April 19, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

Spotlight

Vigilance Biotechnology LLC

Vigilance Biotechnology™ provides medicinal healthcare consultant services and biotechnology business services. The three major service products of Vigilance Biotechnology are: Personal Medicinal Consultant Services The Personal Medicinal Consultant Service provides clients with healthcare information that can help them achieve better health. Vigilance develops custom safety evaluation reports for clients using multiple prescription drugs, over-the-counter (OTC) products, herbal, and dietary supplements. Vigilance suggests dietary supplements as alternatives to prescription medicines that can be used to help achieve better health and athletic performance. Biotechnology Business Plan Services Vigilance Biotechnology provides four unique business plan services to its clients. Vigilance quickly evaluate and strengthen pre-existing biotechnology business plans. We work directly with clients to develop outstanding new biotechnology business plans.

Events